We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
We expect investors to focus on the updates related to CRISPR Therapeutics AG’s (CRSP - Free Report) progress with its pipeline candidates when it reports first-quarter 2022 results.
CRSP’s earnings surpassed expectations in two of the trailing four quarters and missed the same on the other two occasions, with the average surprise being 29.2%. In the last reported quarter, CRISPR Therapeutics witnessed a negative earnings surprise of 5.8%.
In the year so far, shares of CRISPR Therapeutics have declined 26.7% compared with the industry’s 16.4% fall.
Image Source: Zacks Investment Research
Let’s see how things have shaped up for the quarter to be reported.
Factors to Consider
With no marketed product in its portfolio, we expect the focus of the first-quarter conference call to be on the updates related to CRISPR Therapeutics’ pipeline. CRSP’s top line mainly comprises grants and collaboration revenues and on this front, it is mainly dependent on Vertex Pharmaceuticals (VRTX - Free Report) .
As part of its collaboration with Vertex, CRISPR Therapeutics is evaluating CTX001, an investigational ex-vivo CRISPR gene-edited therapy, for sickle cell disease and transfusion-dependent beta thalassemia indications in two separate phase I/II studies. CRISPR Therapeutics and Vertex Pharmaceuticals already achieved the target enrolment in both these studies and intend to file regulatory applications for CTX001 to treat both indications by this year-end.
CRISPR Therapeuticsis also advancing its wholly-owned immuno-oncology pipeline, which currently consists of three chimeric antigen receptor T cell (CAR-T) therapy candidates, namely CTX110, CTX120 and CTX130, for the treatment of hematological and solid-tumor cancers.
CRSP is currently evaluating CTX110 in the phase I CARBON study for the treatment of relapsed/refractory B-cell malignancies. Earlier this February, management announced that CRISPR Therapeutics expanded the ongoing early-stage CARBON study into a pivotal one and implemented consolidation dosing in patients. CRSP is expected to report additional data from this study later this year.
A phase I study is investigating the safety and efficacy of several dose levels of CTX120 for the treatment of relapsed or refractory multiple myeloma. Two ongoing independent phase I studies are also evaluating the safety and efficacy of several dose levels of CTX130 for treating solid tumors and certain hematologic malignancies. Top-line data from all these studies is expected in first-half 2022.
Apart from the above, CRISPR Therapeutics is expanding its ex-vivo expertise in the field of regenerative medicines. In February, management had announced that CRSP dosed the first patient in an early-stage study to evaluate the safety, tolerability and immune evasion of its investigational allogeneic stem cell-derived therapy VCTX210 for the type I diabetes.
Activities related to the development of pipeline candidates are likely to have escalated operating expenses in the to-be-reported quarter.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for CRISPR Therapeuticsthis time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: CRISPR Therapeutics has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of $1.91.
Zacks Rank: CRISPR Therapeutics currently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are a few stocks you may want to consider as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Angion Biomedica’s loss per share estimates for 2022 have narrowed from $2.59 to $1.79 in the past 30 days. The same for 2023 has narrowed from $3.11 to $2.19 in the past 30 days. Earnings of Angion Biomedicabeat estimates in three of the last four quarters and missed the mark once, the average surprise being 47.5%.
Applied Therapeutics (APLT - Free Report) has an Earnings ESP of +21.95% and a Zacks Rank #2 at present.
In the past 30 days, estimates for Applied Therapeutics’2022 loss per share have narrowed from $3.39 to $2.47. The same for 2023 has narrowed from $2.52 to $2.01 in the past 30 days. Earnings of Applied Therapeuticstopped estimates in three of the last four quarters and missed the mark on one occasion, delivering a surprise of 2.6%, on average.
Image: Bigstock
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
We expect investors to focus on the updates related to CRISPR Therapeutics AG’s (CRSP - Free Report) progress with its pipeline candidates when it reports first-quarter 2022 results.
CRSP’s earnings surpassed expectations in two of the trailing four quarters and missed the same on the other two occasions, with the average surprise being 29.2%. In the last reported quarter, CRISPR Therapeutics witnessed a negative earnings surprise of 5.8%.
CRISPR Therapeutics AG Price and EPS Surprise
CRISPR Therapeutics AG price-eps-surprise | CRISPR Therapeutics AG Quote
In the year so far, shares of CRISPR Therapeutics have declined 26.7% compared with the industry’s 16.4% fall.
Image Source: Zacks Investment Research
Let’s see how things have shaped up for the quarter to be reported.
Factors to Consider
With no marketed product in its portfolio, we expect the focus of the first-quarter conference call to be on the updates related to CRISPR Therapeutics’ pipeline. CRSP’s top line mainly comprises grants and collaboration revenues and on this front, it is mainly dependent on Vertex Pharmaceuticals (VRTX - Free Report) .
As part of its collaboration with Vertex, CRISPR Therapeutics is evaluating CTX001, an investigational ex-vivo CRISPR gene-edited therapy, for sickle cell disease and transfusion-dependent beta thalassemia indications in two separate phase I/II studies. CRISPR Therapeutics and Vertex Pharmaceuticals already achieved the target enrolment in both these studies and intend to file regulatory applications for CTX001 to treat both indications by this year-end.
CRISPR Therapeuticsis also advancing its wholly-owned immuno-oncology pipeline, which currently consists of three chimeric antigen receptor T cell (CAR-T) therapy candidates, namely CTX110, CTX120 and CTX130, for the treatment of hematological and solid-tumor cancers.
CRSP is currently evaluating CTX110 in the phase I CARBON study for the treatment of relapsed/refractory B-cell malignancies. Earlier this February, management announced that CRISPR Therapeutics expanded the ongoing early-stage CARBON study into a pivotal one and implemented consolidation dosing in patients. CRSP is expected to report additional data from this study later this year.
A phase I study is investigating the safety and efficacy of several dose levels of CTX120 for the treatment of relapsed or refractory multiple myeloma. Two ongoing independent phase I studies are also evaluating the safety and efficacy of several dose levels of CTX130 for treating solid tumors and certain hematologic malignancies. Top-line data from all these studies is expected in first-half 2022.
Apart from the above, CRISPR Therapeutics is expanding its ex-vivo expertise in the field of regenerative medicines. In February, management had announced that CRSP dosed the first patient in an early-stage study to evaluate the safety, tolerability and immune evasion of its investigational allogeneic stem cell-derived therapy VCTX210 for the type I diabetes.
Activities related to the development of pipeline candidates are likely to have escalated operating expenses in the to-be-reported quarter.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for CRISPR Therapeuticsthis time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: CRISPR Therapeutics has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of $1.91.
Zacks Rank: CRISPR Therapeutics currently carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are a few stocks you may want to consider as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Angion Biomedica currently has an Earnings ESP of +15.71% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Angion Biomedica’s loss per share estimates for 2022 have narrowed from $2.59 to $1.79 in the past 30 days. The same for 2023 has narrowed from $3.11 to $2.19 in the past 30 days. Earnings of Angion Biomedicabeat estimates in three of the last four quarters and missed the mark once, the average surprise being 47.5%.
Applied Therapeutics (APLT - Free Report) has an Earnings ESP of +21.95% and a Zacks Rank #2 at present.
In the past 30 days, estimates for Applied Therapeutics’2022 loss per share have narrowed from $3.39 to $2.47. The same for 2023 has narrowed from $2.52 to $2.01 in the past 30 days. Earnings of Applied Therapeuticstopped estimates in three of the last four quarters and missed the mark on one occasion, delivering a surprise of 2.6%, on average.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.